PURE Bioscience heads into the final days of April trading near $0.069 — a stock that has lost roughly a fifth of its value over the past month, even as it clawed back about 5% this week.
The price tells most of the story here. At just under seven cents a share, with a market cap of roughly $7.7 million, PURE operates in micro-cap territory where conventional short positioning data carries limited signal. Short interest is negligible — barely 3,200 shares, equivalent to just 0.005% of the free float — and availability of shares to borrow is effectively unlimited, with availability running at 9,999% of short interest. There is no meaningful short-seller pressure here, and no squeeze dynamic worth flagging. The ORTEX short score registers 29.8, a moderate reading that has barely moved over the past two weeks, consistent with the static short interest figures that have been flat since mid-April.
One data point worth noting is the days-to-cover reading, which ranks in the 100th percentile of the universe. At one day to cover by official FINRA data, this is a function of extremely thin volume rather than a sign of unusual positioning. Cost-to-borrow data is stale — the last recorded rate of 7.05% dates to mid-December 2025, down from roughly 8.8% earlier in the year — so the current borrow cost cannot be reliably quoted, though the loose availability environment suggests little upward pressure on fees.
The ownership picture is dominated by a single individual — Tom Lee, whose disclosed stake of 44 million shares represents roughly 39% of the company as of December 2025. The remaining identified holders are small, and there has been no reported change in any top position since that date. Institutional data is stale by more than four months, and the most recent insider trades on record date to early 2023, making any ownership narrative a backward-looking one rather than a live signal.
Earnings are due on June 12. In recent prints, the stock has oscillated — a 1.3% one-day gain in March following a quarterly release, a near-10% single-session move in December 2025, and a smaller pullback in the five days that followed. With no analyst coverage to anchor expectations, and valuation data either outdated or absent, there is no Street framework for framing what the June event might deliver beyond the historical pattern of modest, short-lived price reactions.
The next meaningful watch point for PURE is the June 12 earnings release — for a stock this thinly covered, the print itself and any associated commentary on product traction will be the primary price driver in the weeks ahead.
See the live data behind this article on ORTEX.
Open PURE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
